Please use this identifier to cite or link to this item:
http://dr.iiserpune.ac.in:8080/xmlui/handle/123456789/9147
Title: | Immunogenic Sulfated l-Idose Homo Oligosaccharides Elicit Neutralizing Antibody against Native Heparan Sulfate with Biomarker and Therapeutic Possibilities |
Authors: | VISHWESHWARA, SHARATH S. BHOGE, PREETI RAVINDRA ANAND, SAURABH RAIGAWALI, RAKESH CHANDRA, ANKITA Saladi, Srinivas Vinod KIKKERI, RAGHAVENDRA Dept. of Chemistry |
Keywords: | Biopolymers Immunology Ligands Mixtures Peptides and proteins 2024 2024-OCT-WEEK2 TOC-OCT-2024 |
Issue Date: | Oct-2024 |
Publisher: | American Chemical Society |
Citation: | Journal of Medicinal Chemistry, 67(20), 18465–18477. |
Abstract: | Heparan sulfate (HS) is a non-immunogenic antigen, and developing antibodies against specific sulfated patterns in HS poses significant challenges. Herein, we employed an innovative immunization strategy that exploits the molecular mimicry of HS to generate antibodies against HS sequences. Mice were immunized with synthetic sulfated oligo-l-idose (ID49) that mimics optimum 67% of the conserved structure of HS ligands. This immunization of ID49@CRM197 with alum and Freund’s adjuvant resulted in the production of robust IgG antibody responses targeting ID49 and cross-reactivity with the N-sulfated HS ligands compared to N-unsubstituted and N-acetate domain synthetic HS ligands. Such a pharmacological agent exhibited distinct staining of tissue sections and cell lines and induced complement-dependent cell cytotoxicity against SK-BR-3 cancer cells. Moreover, these antibodies inhibited heparin-mediated anticoagulation activity similar to that of protamine. These findings highlight the biomarker and possible therapeutic capability of the antibodies. |
URI: | https://doi.org/10.1021/acs.jmedchem.4c01772 http://dr.iiserpune.ac.in:8080/xmlui/handle/123456789/9147 |
ISSN: | 0022-2623 1520-4804 |
Appears in Collections: | JOURNAL ARTICLES |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.